Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2‐week‐on and 1‐week‐off schedule
Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2‐week‐on and 1‐week‐off schedule
复制标题
DOI：
10.1111/jcpt.13517
复制
发表时间：
2021-10
影响因子：
2
通讯作者：
Takahiro Ito;Kazuhiro Yamamoto;J. Furukawa;K. Harada;M. Fujisawa;T. Omura;I. Yano
中科院分区：
文献类型：
--
作者：
Takahiro Ito;Kazuhiro Yamamoto;J. Furukawa;K. Harada;M. Fujisawa;T. Omura;I. Yano
舒尼替尼被用作转移性肾细胞癌的一线治疗。本研究的主要目的是确定替代给药方案的最佳总舒尼替尼（舒尼替尼加N -去乙基舒尼替尼）谷浓度：2周服用和1周停用方案（2/1方案）。
Sunitinib is used as a first‐line therapy for metastatic renal cell carcinoma. The primary aim of this study was to determine the optimal total sunitinib (sunitinib plus N‐desethyl sunitinib) trough concentration for the alternative dosing schedule: 2‐week‐on and 1‐week‐off schedule (2/1 schedule).